{"schema_version":"1.0","type":"article","title":"40年沒藥的遺傳病迎來重磅進展","url":"https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing.md","lang":"zh-Hant","date":"2026-06-03","publish_at":"2026-06-03T10:30:00+08:00","updated_at":"2026-06-03","category":"商業分析系列","topic":"臨床與 CMC","tags":["AATD","罕見疾病","Sanofi","Wave Life Sciences","Beam Therapeutics","RNA 編輯","基因編輯"],"summary":"AATD 治療在近 40 年後迎來新療法競速，Sanofi、Wave、Beam 分別以長效重組蛋白、RNA 編輯與基因鹼基編輯切入，代表罕見遺傳病治療正從補蛋白走向根源修正。","key_points":[],"facts":[],"sections":["打破 40 年僵局：AATD 迎來新療法競速，從補蛋白走向基因修正","01｜AATD 是什麼？一個同時傷肺與傷肝的單基因疾病","02｜一個被低估的藍海：患者不少，但診斷率極低","03｜Sanofi：重組蛋白 efdoralprin alfa，先把傳統補充療法做得更好","04｜Wave：WVE-006 用 RNA 編輯，讓肝臟重新生產健康 AAT","05｜Beam：BEAM-302 走得更遠，直接在 DNA 層級修正突變","06｜Fazirsiran：另一條路，先處理肝臟裡的錯誤蛋白","07｜AATD 治療新格局：四種策略正在同時成形","08｜真正的關鍵，不是誰技術最炫，而是誰能回答肺與肝兩個問題","09｜台灣可以怎麼看？沒有直接標的，但有兩個產業啟示","結語｜AATD 從別無選擇，走向多路線競爭"],"references":[],"images":[{"alt":"AATD 治療正在從傳統補蛋白，走向長效重組蛋白、RNA 編輯與基因編輯並行的新競賽。","url":"https://drugnews.com.tw/assets/articles/aatd-new-therapy-rna-gene-editing/dcard-01.webp"},{"alt":"Sanofi、Wave 與 Beam 分別代表不同技術路徑，也對應不同的風險、療效與商業化想像。","url":"https://drugnews.com.tw/assets/articles/aatd-new-therapy-rna-gene-editing/dcard-02.webp"},{"alt":"罕見遺傳病的下一階段，不只是補足缺失蛋白，而是能否安全、持久地修正疾病根源。","url":"https://drugnews.com.tw/assets/articles/aatd-new-therapy-rna-gene-editing/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/aatd-new-therapy-rna-gene-editing/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-03）。40年沒藥的遺傳病迎來重磅進展。https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-03-aatd-new-therapy-rna-gene-editing-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}